Peter is a co-founder of Numab. He holds an MD as well as a PhD in Molecular Biology from the University of Zurich. In 2000 Peter joined ESBATech AG to hold various positions in preclinical and clinical research. In 2004 he was appointed Medical Director and Head of Clinical Research and Development, leading several preclinical development projects with antibody fragments in oncology, inflammatory and neurodegenerative diseases. He developed ESBATech’s “body compartment concept” aimed at the optimal therapeutic exploitation of the pharmacokinetic properties of antibody fragments. He designed and led clinical development programs in ophthalmology and rheumatology with ESBA105 and ESBA1008, TNF-inhbitory and VEGF-inhibitory antibody fragments, respectively. Peter joins from Sucampo, where from 2011 he was Senior Medical Officer and Vice President European Operations. He co-authored a great number of peer-reviewed publications.
Molecular Biology